Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.

Slides:

Advertisements

Similar presentations

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Advertisements

Subchorionic hematomas are increased in early pregnancy in women taking low-dose aspirin Ashley Truong, B.S., M. Mercedes Sayago, M.D., William H. Kutteh,

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.

Antagonists in poor-responder patients

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Nicole Banks, M. D. , George Patounakis, M. D. , Ph. D

Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger? Matthew.

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization.

Karl R. Hansen, M. D. , Ph. D. , George M. Hodnett, M. D

The predictive value for in vitro fertility delivery rates is greatly impacted by the method used to select the threshold between normal and elevated.

Michael M. Alper, M.D. Fertility and Sterility

Mike Ripley, M. D. , F. R. C. S. C. , Andrea Lanes, M. Sc

Karen Purcell, M. D. , Ph. D. , Michael Schembri, M. S. , Linda M

James P Toner, M.D., Ph.D. Fertility and Sterility

Patient-tailored ovarian stimulation for in vitro fertilization

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women Carlos Iglesias, M.D., Manish Banker, M.D.,

Role of ovarian reserve markers, antimüllerian hormone and antral follicle count, as aneuploidy markers in ongoing pregnancies and miscarriages Maribel.

Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained.

The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society.

Orhan Bukulmez, M. D. , Qin Li, M. S. , Bruce R. Carr, M. D

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count Simone L. Broer, B.Sc., Ben Willem J.

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.

Antral follicle count: absence of significant midlife decline

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Modification of the Beckman-Coulter second-generation enzyme-linked immunosorbent assay protocol improves the reliability of serum antimüllerian hormone.

Influences on endometrial development during intrauterine insemination: clinical experience of 2,929 patients with unexplained infertility Erin Foran.

Albert Hsu, M. D. , Margaret Arny, Ph. D. , Alexander B. Knee, M. S

Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study Frederic Mitri,

A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization Laura Detti, M.D., Daniel B. Williams, M.D., Jared.

Subchorionic hematomas are increased in early pregnancy in women taking low-dose aspirin Ashley Truong, B.S., M. Mercedes Sayago, M.D., William H. Kutteh,

Sean Ackerman, M. D. , Julia Wenegrat, M. A. , David Rettew, M. D

A new approach to ovarian reserve testing

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation Nam D. Tran, M.D., Ph.D., Lusine Aghajanova, M.D.,

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception Lauren N.C. Johnson,

Stephanie L. F. Gustin, M. D. , Gourab Mukherjee, Valerie L. Baker, M

Birth outcomes after spontaneous or assisted conception among infertile Australian women aged 28 to 36 years: a prospective, population-based study Danielle.

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities.

M. Kathleen Clark, Ph. D. , MaryFran R. Sowers, Ph. D

Vasiliki A. Moragianni, M. D. , M. S. , Stephanie-Marie L. Jones, M. D

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Stephanie A. Beall, M.D., Ph.D., Alan DeCherney, M.D.

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization David W. Schmidt, M.D.,,

Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic.

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Lapse in embryo transfer training does not negatively affect clinical pregnancy rates for reproductive endocrinology and infertility fellows Jessica.

Eric S. Surrey, M. D. , Debra A. Minjarez, M. D. , John M. Stevens, B

A woman with premature ovarian failure induced by Tripterygium wilfordii Hook.f. gives birth to a healthy child Xin Chen, M.D., M.Sc., Shi-ling Chen,

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories Melissa C. Yih, M.D.,

Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D

Cumulative live birth rates in cohorts of patients treated with in vitro fertilization or intracytoplasmic sperm injection Cynthia Witsenburg, M.D.,

Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve Norbert.

Conversion from assisted reproductive technology to intrauterine insemination in low responders: Is it advantageous? John M. Norian, M.D., Eric D. Levens,

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.

Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:

Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated.

Presentation transcript:

Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss in younger in vitro fertilization patients Lauren A. Bishop, M.D., Kevin S. Richter, Ph.D., George Patounakis, M.D., Ph.D., Leslie Andriani, M.D., Kimberly Moon, M.D., Kate Devine, MD Fertility and Sterility Volume 108, Issue 6, Pages 980-987 (December 2017) DOI: 10.1016/j.fertnstert.2017.09.011 Copyright © 2017 Terms and Conditions

Figure 1 Clinical outcomes according to Society for Assisted Reproductive Technology age group and ovarian reserve (FSH or antral follicle count [AFC]) groups: biochemical pregnancy losses subdivided by (A) FSH group and (B) AFC group; clinical pregnancy losses subdivided by (C) FSH group and (D) AFC group; live births subdivided by (E) FSH group and (F) AFC group; and aneuploidy rates among pregnancy loss products of conception subdivided by (G) FSH group and (H) AFC group. Error bars indicate 95% confidence intervals. *P<.05. Fertility and Sterility 2017 108, 980-987DOI: (10.1016/j.fertnstert.2017.09.011) Copyright © 2017 Terms and Conditions

Figure 2 Live birth outcomes according to Society for Assisted Reproductive Technology age group and FSH category. (A) Observed live births per early pregnancy with normal (<10 mIU/mL) versus elevated (≥10 mIU/mL) baseline serum FSH; error bars indicate 95% confidence intervals. *P=.053 for normal versus elevated FSH among patients aged 41–42 years. (B) Relative difference in birth rates in patients with elevated compared with normal baseline serum FSH. Fertility and Sterility 2017 108, 980-987DOI: (10.1016/j.fertnstert.2017.09.011) Copyright © 2017 Terms and Conditions

Figure 3 Observed live birth rates per early pregnancy by age at pregnancy (blue). Fitted logistic regression models based on untransformed age data (red) and age data transformed according to the formula 1/(47 − age) (black), and associated R2 values, are superimposed for comparison. Fertility and Sterility 2017 108, 980-987DOI: (10.1016/j.fertnstert.2017.09.011) Copyright © 2017 Terms and Conditions